PharmEasy investor cuts value of its stake drastically, implying new valuation of $456M

PharmEasy Investor Slashes Stake Value, New Valuation Drops to $456M.

Expert Analysis:

• New Valuation: PharmEasy is now valued at $456 million, based on Janus Henderson’s filing, which values its 12.9 million shares at $766,043.

• Original Investment and Valuation Drop: Janus Henderson’s Global Research Fund originally spent $9.4 million to acquire the shares, with the current valuation down 92% from PharmEasy’s all-time high of $5.6 billion.

• Fresh Capital and IPO Plans: Despite raising over $200 million in fresh capital earlier this year, the valuation remains low as PharmEasy prepares to file for an initial public offering next year.

• Rights Issue and Capital Raised: In 2023, PharmEasy raised $417 million through a rights issue amidst a funding crunch, with $216 million secured by April 2024.

• Backers and Market Position: PharmEasy, backed by Prosus, Temasek, TPG, and B Capital, operates one of India’s largest online pharmacies.

• Thyrocare Acquisition: PharmEasy's current valuation is much lower than the $600 million it paid to acquire Thyrocare in 2021. 

• Financial Challenges: After deferring an $843 million IPO in 2021, PharmEasy struggled with debt, including a $300 million loan from Goldman Sachs, and difficulties raising new equity in a tough market.